3-MPPI
3-MPPI is a GPCR ligand with high selectivity for α1-adrenergic receptor, with a Ki value of 0.21 nM for α1-adrenergic receptor and 50 nM for 5-HT1A receptor. 3-MPPI modulates the α1-adrenergic receptor signaling cascade. 3-MPPI is applicable to research related to hypertension, stress-induced anxiety-like behavioral responses, and levodopa-induced dyskinesia.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 133399-65-2
- Fòrmula: C23H25N5O3
- Peso molecular:419.49
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | Inhibition |
9.14 %
Compound: 3-MPPI
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
10.21203/rs.3.rs-23951/v1 |
In Vitro
3-MPPI (compound RN5) derivatives exhibit exceptional α1-adrenoceptor (α1-AR) affinity (Ki = 2.71 nM) and selectivity over 5-HT1A receptors (5-HT1A/α1 ratio > 3500)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
No. CAS 133399-65-2
-
Peso molecular 419.49
-
Fòrmula C23H25N5O3
-
SMILES
O=C1NC=2C=3C=CC=CC3NC2C(=O)N1CCN4CCN(C=5C=CC=CC5OC)CC4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
3-MPPI Related Classifications
HY-101008 Related Classifications
Powered by Bioz
Keywords
- 3-MPPI
- 133399-65-2
- Adrenergic Receptor
- G protein-coupled Bile Acid Receptor 1
- benign prostatic hyperplasia
- stress-induced anxiety-like behavioral responses
- l-dopa-induced dyskinesia
- GPCR ligand
- α1-adrenoceptor
- lower urinary tract symptoms
- hypertension
- myocardial hypertrophy
- 5-HT1A receptor
- human α1?-AR
- Inhibitor
- inhibitor
- inhibit